Consolidated Guidelines

Acknowledgements

The production and writing of the WHO consolidated guidelines on tuberculosis. Module 6: TB and comorbidities were coordinated by Annabel Baddeley, Anna Carlqvist and Kerri Viney, under the guidance of Farai Mavhunga and overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global Tuberculosis Programme.

Introduction to the consolidated guidelines on tuberculosis – Module 6

Globally, tuberculosis (TB) remains a significant cause of ill health and is a leading cause of death due to an infectious agent (1). Five main health-related risk factors, namely, diabetes mellitus (diabetes), HIV, smoking, undernutrition and disorders due to alcohol use, account collectively for just under half of all new TB episodes globally. The contribution of these risk factors to the global TB burden is reported annually in the WHO’s Global tuberculosis report (1).

A5.4 A survey to explore the programmatic feasibility of levofloxacin (Lfx) TPT for MDR-TB contacts11

Introduction

The survey assessed the feasibility of programmatic use of Lfx for TPT among contacts of MDR-TB patients in the eventuality of a WHO recommendation for its programmatic use. The objective was to collect perspectives from national TB programmes (NTPs), explore current practices for MDR TPT, its programmatic feasibility, affordability, impact on equity, acceptability to patients and health-care workers and to inform the discussion of WHO Guideline group at its meeting on 4–6December 2023.

Methods

A5.1 Summary of TB CHAMP and V-QUIN clinical trials

Tuberculosis Child Multidrug-Resistant Preventive Therapy Trial (TB CHAMP): Efficacy and safety of levofloxacin preventive treatment in child and adolescent HHCs of multidrug-resistant tuberculosis (MDR-TB). Author: Anneke Hesseling⁷

V-QUIN MDR-TB prevention study: Levofloxacin versus placebo for the treatment of tuberculosis infection among contacts of patients with MDR-TB. Author: Greg Fox⁸

Methods

Subscribe to Consolidated Guidelines